Myriad Genetics Inc. said the phase III POLO study demonstrated its BRACAnalysis CDx test successfully identified patients with metastatic pancreatic cancer who have BRCA mutations and benefitted from treatment with olaparib, a novel PARP inhibitor.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
